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Estrogen for Men: Reversal of
Cardiovascular Misfortune?*
ALAN C. YEUNG, MD, FACC
Stanford, California
The difference in cardiovascular morbidity and mortality be-
tween gender is unrefutable (1,2). Multiple studies have dem-
onstrated that the female gender provides substantial protec-
tion against myocardial infarction, strokes and sudden death.
This protection is lost after menopause but is partially restored
with estrogen therapy (3). Therefore, it seems reasonable to
assume that estrogen is the major effector of this protection.
Conflicting data have existed in published reports as to
whether estrogen therapy can protect men against cardiovas-
cular events. Some of these studies are confounded by the age
of the subjects and their underlying disease states. Clinical
studies using cardiovascular end points are also difficult to
organize due to a lack of suitable subjects and the prohibitive
sample size requirement. In recent years, the testing of endo-
thelial function as a marker of early atherosclerosis has been
popularized. However, the need for invasive techniques (e.g.,
coronary angiography) made it impractical to screen patients
with early disease. A new technique, developed by Celermajer
et al. (4), has been to use the brachial artery flow-mediated
vasodilation response as a surrogate test for endothelial func-
tion, thereby allowing extrapolation to the functional state of
the more relevant vascular trees.
New et al. (5) and McCrohon et al. (6) in this issue of the
Journal independently studied two populations of male to
female transsexuals in Melbourne and Sidney, Australia, main-
tained on high dose estrogen with and without antiandrogen
therapy. The Melbourne group studied 14 male to female
transsexuals, 14 age-matched men and 14 age-matched pre-
menopausal women. The transsexuals had been receiving
estrogen therapy for 61 6 70 months; 21% had orchidectomy,
and the rest received antiandrogen therapy. Six transsexuals
had coronary risk factors (smoking, family history, diabetes,
hypercholesterolemia). The flow-mediated response in the
transsexuals, women and men was 11.5 6 1.3% versus 9.4 6
1.1% versus 5.2 6 1.0%, with baseline diameters of 4.1, 3.6 and
4.9 mm, respectively. The nitroglycerin response was also
significantly different: 21.6 6 1.7% versus 21.0 6 0.9% versus
14.5 6 1.2%. The duration of therapy was not predictive, and
only estrogen therapy (testosterone level) and vessel size were
predictive of the brachial responses. The Sidney group studied
15 male to female transsexuals and 15 men, well matched for
age, smoking history and rest vessel size (4.0 vs. 4.2 mm). The
transsexuals had been receiving estrogen for 6 months to 21
years, with concomitant orchidectomy (50%) and antiandro-
gen therapy (50%). The flow-mediated response was markedly
better in the transsexuals than in the control subjects (7.1 6
3.1% vs. 3.2 6 2.8%), with an equally impressive improvement
in vasodilation response to nitroglycerin (21.2 6 6.7% vs.
14.6 6 3.3%). Both of these improvements were not related to
the duration of estrogen treatment. In summary, both studies
showed that male to female transsexuals have better arterial
function (endothelial dependent and independent) as mea-
sured by brachial ultrasound.
Mechanisms of benefit. The nature of these correlative
studies do not allow them to distinguish whether the vascular
functional improvement is due to the estrogen effect or the
androgen-depleted states because these two interventions si-
multaneously occurred in all transsexual patients. However, it
is still interesting that with proper hormonal intervention, the
vasculature of the male can be made to behave like that of the
female. The inability in both studies to measure the equine
estrogen level hampers any attempt to correlate the arterial
vasodilator responses to the serum estrogen levels, thereby
linking the therapeutic response more closely to estrogen
therapy. Studies in older men being treated for prostate cancer
(either chemically or surgically) suggest (7) that at least a
component of endothelial-dependent vascular improvement is
due to the lack of androgen, whereas the non–endothelial-
dependent function may be due to the estrogen effect. Studies
have also shown (8) that estrogen seems to reverse endothelial
dysfunction in women but not in men; this may be due to the
need of both estrogen supplementation and androgen depri-
vation for vascular improvement to occur. Experimental stud-
ies (9,10) seem to suggest that estrogen enhances endothelium-
dependent nitric oxide–mediated vasodilation. This could be
due to a reduction in nitric oxide sequestration by oxygen-
derived free radicals. Estrogen can modify the lipid profile (11)
and monocyte adhesion to endothelial cells and prevent oxi-
dation of low and high density lipoprotein. The vascular
biology of how estrogen interacts with endothelial cells and
with smooth muscle cells is currently an active area of research.
Clinical implications. Should we be treating men with
coronary artery disease with estrogen? Probably not, because
the “cardioprotective effect” in men will be hard to demon-
strate in the clinical setting without significant feminization
and other side effects, such as a prothrombotic state. However,
these correlative studies may help to generate further interest
in and study of the mechanism of how sex hormones influence
vascular function. In studying the similarities and differences
between the two groups of sex hormones, future investigators
may be able to develop a molecule that can be vascular
protective yet devoid of feminization properties.
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